Metraipolis › archive › dc_798793aa10df

Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study — Europe PMC PMID:42404437

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42404437
DOI
10.1016/j.eclinm.2026.104021
License (as archived)
solo-consultazione
Archived
2026-10-31T07:31:50.883Z
SHA-256 of the archived text
92c6f49f183a9c3ee3894f6b9767e92d63d3765c16679668116c8be4dc3546ce
Stable URL of this page
https://metraipolis.com/documento/dc_798793aa10df

How to cite

Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study — Europe PMC PMID:42404437 — Europe PMC (en), https://europepmc.org/article/MED/42404437 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_798793aa10df (Metraipolis archive dc_798793aa10df, sha256 92c6f49f183a9c3ee3894f6b9767e92d63d3765c16679668116c8be4dc3546ce)
BibTeX
@misc{dc798793aa10df,
  title = {Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study — Europe PMC PMID:42404437},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42404437},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_798793aa10df; sha256 92c6f49f183a9c3ee3894f6b9767e92d63d3765c16679668116c8be4dc3546ce},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42404437. Agents can read the archived copy with the MCP tool read_document.